Skip to content
What We Do
For Providers
Model-Informed Precision Dosing
Clinical Decision Support
Real-Time Clinical Analytics
Infectious Disease
Bone Marrow Transplant
Other Therapeutic Areas
Customers
For Biopharma
Precision Dosing in Clinical Trials
Real-time Pharmacology Analytics in Clinical Trials
Companion Applications
How We Do It
InsightRX Nova
InsightRX Apollo
Continuous Learning
Integrations
Drug Modules
Security
Company
Mission & Values
Leadership
Careers
Press Releases
Press Releases
Media
Resources
Product Innovation
Scientific Publications
Thought Leadership
White Papers
Contact Us
FEATURED
Choosing the right model for your patient: An introduction to InsightRX Gemini
Resources
Thought Leadership
Jan 12, 2024
Improving Hospital Workflows by Integrating a Precision Dosing Platform with EHRs
Thought Leadership
Aug 15, 2023
Simulation Demonstrates Potential Effectiveness of Model-Informed Precision Dosing for Heparin
Thought Leadership
Feb 28, 2023
What Does 2023 Hold for Biopharma? Part 5: Technological Advances
Thought Leadership
Jan 3, 2023
The 2023 PharmaVoice Crystal Ball: Peering into the future of life sciences
Thought Leadership
Dec 16, 2022
What to Expect from AI-Enabled Drug Discovery in 2023
Thought Leadership
Jul 18, 2022
Understanding Project Optimus
Thought Leadership
Apr 6, 2022
Understanding FDA’s Perspective On Precision Dosing
Scientific Publications
Aug 1, 2020
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse
Scientific Publications
Jul 20, 2020
Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population
1
2
